250 related articles for article (PubMed ID: 33507250)
21. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
22. Changes in the serotype distribution of Streptococcus pneumoniae causing otitis media after PCV13 introduction in Spain.
Morales M; Ludwig G; Ercibengoa M; Esteva C; Sanchez-Encinales V; Alonso M; Muñoz-Almagro C; Marimón JM
PLoS One; 2018; 13(12):e0209048. PubMed ID: 30562385
[TBL] [Abstract][Full Text] [Related]
23. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
24. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
[TBL] [Abstract][Full Text] [Related]
25. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
26. Pneumococcal conjugate vaccines for preventing acute otitis media in children.
Fortanier AC; Venekamp RP; Boonacker CW; Hak E; Schilder AG; Sanders EA; Damoiseaux RA
Cochrane Database Syst Rev; 2019 May; 5(5):CD001480. PubMed ID: 31135969
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
[TBL] [Abstract][Full Text] [Related]
28. Changes in Otitis Media Episodes and Pressure Equalization Tube Insertions Among Young Children Following Introduction of the 13-Valent Pneumococcal Conjugate Vaccine: A Birth Cohort-based Study.
Wiese AD; Huang X; Yu C; Mitchel EF; Kyaw MH; Griffin MR; Grijalva CG
Clin Infect Dis; 2019 Nov; 69(12):2162-2169. PubMed ID: 30770533
[TBL] [Abstract][Full Text] [Related]
29. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
30. Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease.
Izurieta P; Nieto Guevara J
Hum Vaccin Immunother; 2022 Dec; 18(1):1872341. PubMed ID: 33605846
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study.
Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G;
Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of the 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in South African children: a case-control study.
Cohen C; von Mollendorf C; de Gouveia L; Lengana S; Meiring S; Quan V; Nguweneza A; Moore DP; Reubenson G; Moshe M; Madhi SA; Eley B; Hallbauer U; Finlayson H; Varughese S; O'Brien KL; Zell ER; Klugman KP; Whitney CG; von Gottberg A;
Lancet Glob Health; 2017 Mar; 5(3):e359-e369. PubMed ID: 28139443
[TBL] [Abstract][Full Text] [Related]
33. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
[TBL] [Abstract][Full Text] [Related]
34. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
35. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
36. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland.
Allemann A; Frey PM; Brugger SD; Hilty M
Vaccine; 2017 Apr; 35(15):1946-1953. PubMed ID: 28279564
[TBL] [Abstract][Full Text] [Related]
37. The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.
Mokaddas E; Syed S; Albert MJ
Hum Vaccin Immunother; 2021 Nov; 17(11):4661-4666. PubMed ID: 34435932
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of Pneumococcal Conjugate Vaccines Against Community-acquired Alveolar Pneumonia Attributable to Vaccine-serotype Streptococcus pneumoniae Among Children.
Lewnard JA; Givon-Lavi N; Dagan R
Clin Infect Dis; 2021 Oct; 73(7):e1423-e1433. PubMed ID: 33346348
[TBL] [Abstract][Full Text] [Related]
39. Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era.
Kaplan SL; Center KJ; Barson WJ; Ling-Lin P; Romero JR; Bradley JS; Tan TQ; Hoffman JA; Peters TR; Gurtman A; Scott DA; Trammel J; Gruber WC; Hulten KG; Mason EO
Clin Infect Dis; 2015 May; 60(9):1339-45. PubMed ID: 25648240
[TBL] [Abstract][Full Text] [Related]
40. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
